Reshaping biopsy and needle-based therapy through
Prostate cancer is the second most common cancer in men.
In Europe, around 1 million prostate biopsies are carried out each year. Biopsy is still affected by diagnostic errors between 30% and 50%. The main sources of error are target detection and needle insertion: both operator dependent! We aim to radically improve the clinical outcome in needle based prostate biopsy procedures by using AI and robotics, turning an operator-dependent procedure into a safe, accurate and repeatable robot-assisted procedure.
Target Identification and planning
The following features represent a competitive advantage compared to other similar devices in the market, moreover we adhere to the international guidelines towards transsperineal biopsy.